STATEMENT OF NEED
Hepatocellular carcinoma is the sixth most common tumor globally, with an increasing incidence in the United States and Europe. The malignancy is the third leading cause of cancer-related death worldwide and the leading cause of death in patients with cirrhosis. Approximately 40,710 new cases are diagnosed in the United States annually and 28,920 people die of the disease. Patients with HCC continue to have a dismal prognosis, with a 5-year survival rate of 18%. This is due in part to most tumors being diagnosed at advanced stages, for which there is a dearth of effective treatment options.
Medical oncologists, hepatologists, gastroenterologists, oncology nurse practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with hepatocellular carcinoma.
Upon completion of this activity, participants should be able to:
- Describe the pathogenesis of HCC and the scientific foundation for antiangiogenic therapies
- Evaluate emerging efficacy and safety data on the use of antiangiogenic therapies for patients with advanced HCC
- Assess tumor response in patients receiving antiangiogenic therapies for advanced HCC
Thomas A. Abrams, MD (Chairperson)
Assistant Professor of Medicine
Harvard Medical School
There is no fee to participate in or claim CME/CE credit for this activity.
Jointly Provided by
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and i3 Health. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine. Designated for 0.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN® renewal candidates: 1 ILNA point may be applied toward:
Scientific Basis/Diagnosis or Treatment Modalities or Professional ......................................................1 point
AOCNP® and AOCNS® renewal candidates: 1 ILNA point may be applied toward:
Scientific Basis/Diagnosis or Treatment Modalities or Professional or Roles of the APN ...................1 point
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Thomas A. Abrams, MD has served as a consultant for Bayer, Bristol-Myers Squibb, Celgene, Aduro, and Kaleido, and has received grants/research support from Eli Lilly and Celgene.
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. i3 Health planners and managers have no relevant financial relationships to disclose.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
- Take the pretest
- Watch the online video
- Pass the posttest with a score of ≥80%
- Complete the activity evaluation
- Download or print their Certificate of Credit
UNAPPROVED USE DISCLOSURE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Bayer Healthcare Pharmaceuticals Inc.